cached image

Mark A. Wainberg - Publications

Affiliations: 
McGill University, Montreal, QC, Canada 
Area:
Microbiology Biology
Website:
https://www.miamiherald.com/news/local/community/gay-south-florida/article144222904.html

304 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA. Erratum for Mesplède et al., "The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration". Mbio. 9. PMID 30254122 DOI: 10.1128/mBio.01450-18  0.52
2018 Osman N, Mesplède T, Oliveira M, Hassounah S, Wainberg MA, Brenner BG. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout. Aids (London, England). PMID 29894388 DOI: 10.1097/QAD.0000000000001903  0.4
2018 Han Y, Mesplède T, Xu H, Quan Y, Wainberg MA. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. Journal of Medical Virology. PMID 29315671 DOI: 10.1002/jmv.25031  0.56
2017 Oliveira M, Brenner BG, Xu H, Ibanescu RI, Mesplède T, Wainberg MA. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA. The Journal of Antimicrobial Chemotherapy. PMID 28961903 DOI: 10.1093/jac/dkx280  0.56
2017 Hassounah SA, Alikhani A, Oliveira M, Bharaj S, Ibanescu RI, Osman N, Xu HT, Brenner BG, Mesplède T, Wainberg MA. Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1. Antimicrobial Agents and Chemotherapy. PMID 28923862 DOI: 10.1128/AAC.01695-17  0.4
2017 Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA. Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication(). Scientific Reports. 7: 6345. PMID 28740124 DOI: 10.1038/s41598-017-06612-2  0.56
2017 Brenner BG, Ibanescu RI, Oliveira M, Roger M, Hardy I, Routy JP, Kyeyune F, Quiñones-Mateu ME, Wainberg MA. HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. The Journal of Antimicrobial Chemotherapy. PMID 28472323 DOI: 10.1093/jac/dkx118  0.4
2017 Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. Mbio. 8. PMID 28377526 DOI: 10.1128/mBio.00157-17  0.52
2017 Quan Y, Xu H, Han Y, Mesplède T, Wainberg MA. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope Mutated HIV-1. Journal of Virology. PMID 28202754 DOI: 10.1128/JVI.00075-17  0.56
2017 Xu HT, Hassounah SA, Colby-Germinario SP, Oliveira M, Fogarty C, Quan Y, Han Y, Golubkov O, Ibanescu I, Brenner B, Stranix BR, Wainberg MA. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. The Journal of Antimicrobial Chemotherapy. PMID 28069884 DOI: 10.1093/jac/dkw514  0.56
2016 Brenner BG, Ibanescu RI, Hardy I, Stephens D, Otis J, Moodie E, Grossman Z, Vandamme AM, Roger M, Wainberg MA. Large cluster outbreaks sustain the HIV epidemic among men having sex with men (MSM) in Quebec from 2002 to 2015. Aids (London, England). PMID 28005684 DOI: 10.1097/QAD.0000000000001383  0.4
2016 Han YS, Penthala NR, Oliveira M, Mesplède T, Xu H, Quan Y, Crooks PA, Wainberg MA. Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. Journal of Medical Virology. PMID 27509184 DOI: 10.1002/jmv.24660  0.56
2016 Isitman G, Lisovsky I, Tremblay-McLean A, Kovacs C, Harris M, Routy JP, Bruneau J, Wainberg MA, Tremblay C, Bernard NF. Antibody dependent cellular cytotoxicity activity of effector cells from HIV infected Elite and Viral Controllers. Aids Research and Human Retroviruses. PMID 27499379 DOI: 10.1089/AID.2016.0157  1
2016 Oliveira M, Ibanescu RI, Pham HT, Brenner B, Mesplède T, Wainberg MA. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. Aids (London, England). PMID 27367488 DOI: 10.1097/QAD.0000000000001191  0.4
2016 Liang C, Wainberg MA, Das AT, Berkhout B. CRISPR/Cas9: a double-edged sword when used to combat HIV infection. Retrovirology. 13: 37. PMID 27230886 DOI: 10.1186/s12977-016-0270-0  0.52
2016 Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, Wainberg MA, Liang C. CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell Reports. PMID 27068471 DOI: 10.1016/j.celrep.2016.03.042  0.52
2016 Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. The Journal of Antimicrobial Chemotherapy. PMID 27029845 DOI: 10.1093/jac/dkw071  0.4
2016 Wainberg MA. Early HIV treatment to forestall drug resistance. The Lancet. Infectious Diseases. PMID 26831126 DOI: 10.1016/S1473-3099(16)00013-X  1
2016 Mesplède T, Wainberg MA. Will LEDGIN molecules be able to play a role in a cure for HIV infection? Ebiomedicine. 8: 14-15. DOI: 10.1016/j.ebiom.2016.05.007  1
2015 Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, ... ... Wainberg MA, et al. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. Plos One. 10: e0145772. PMID 26717411 DOI: 10.1371/journal.pone.0145772  1
2015 Wainberg MA, Mesplede T. Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy. Journal of the International Aids Society. 18: 20824. PMID 26642452 DOI: 10.7448/IAS.18.1.20824  1
2015 Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, ... ... Wainberg MA, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. The New England Journal of Medicine. 373: 2237-2246. PMID 26624850 DOI: 10.1056/NEJMoa1506273  1
2015 Xu HT, Colby-Germinario SP, Hassounah S, Quashie PK, Han Y, Oliveira M, Stranix BR, Wainberg MA. Identification of a pyridoxine-derived small-molecule inhibitor targeting dengue virus RNA-dependent RNA polymerase. Antimicrobial Agents and Chemotherapy. PMID 26574011 DOI: 10.1128/AAC.02203-15  0.56
2015 Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiology. 10: 1773-82. PMID 26517190 DOI: 10.2217/fmb.15.106  1
2015 Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplède T, Wainberg MA. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. Journal of Virology. 89: 12002-13. PMID 26378179 DOI: 10.1128/JVI.02131-15  0.4
2015 Oliveira M, Mesplède T, Moïsi D, Ibanescu RI, Brenner B, Wainberg MA. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. Aids (London, England). 29: 2255-60. PMID 26372484 DOI: 10.1097/QAD.0000000000000866  0.4
2015 Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA. The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high level viral replication and the development of high-level drug resistance. Journal of Virology. PMID 26311878 DOI: 10.1128/JVI.01881-15  0.4
2015 Isitman G, Lisovsky I, Tremblay-McLean A, Parsons MS, Shoukry NH, Wainberg MA, Bruneau J, Bernard NF. Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity. Aids (London, England). 29: 1433-43. PMID 26244383 DOI: 10.1097/QAD.0000000000000729  1
2015 Mesplède T, Wainberg MA. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses. 7: 3703-18. PMID 26198244 DOI: 10.3390/v7072790  1
2015 Han YS, Xiao WL, Xu H, Kramer VG, Quan Y, Mesplède T, Oliveira M, Colby-Germinario SP, Sun HD, Wainberg MA. Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor. Antiviral Chemistry & Chemotherapy. 24: 28-38. PMID 26149264 DOI: 10.1177/2040206614566580  0.56
2015 Osman N, Mesplède T, Quashie PK, Oliveira M, Zanichelli V, Wainberg MA. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. The Journal of Antimicrobial Chemotherapy. 70: 2810-5. PMID 26142476 DOI: 10.1093/jac/dkv176  0.4
2015 Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA. HIV-1 Group O Resistance Against Integrase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999). 70: 9-15. PMID 26017662 DOI: 10.1097/QAI.0000000000000698  0.4
2015 Han YS, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA. A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor. Journal of Medical Virology. 87: 2054-60. PMID 25989218 DOI: 10.1002/jmv.24271  0.56
2015 Wainberg MA, Han YS. Will drug resistance against dolutegravir in initial therapy ever occur? Frontiers in Pharmacology. 6: 90. PMID 25972810 DOI: 10.3389/fphar.2015.00090  1
2015 Yu JH, Wang GC, Han YS, Wu Y, Wainberg MA, Yue JM. Limonoids with Anti-HIV Activity from Cipadessa cinerascens. Journal of Natural Products. 78: 1243-52. PMID 25970729 DOI: 10.1021/acs.jnatprod.5b00025  1
2015 Mesplède T, Moïsi D, Oliveira M, Ibanescu I, Ohnona F, Brenner B, Wainberg MA. Dolutegravir inhibits HIV-1 Env evolution in primary human cells. Aids (London, England). 29: 659-65. PMID 25849829 DOI: 10.1097/QAD.0000000000000606  0.4
2015 Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology. 12: 22. PMID 25808449 DOI: 10.1186/s12977-015-0150-z  0.52
2015 Xu HT, Colby-Germinario SP, Quashie PK, Bethell R, Wainberg MA. Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor. Antimicrobial Agents and Chemotherapy. 59: 3189-96. PMID 25779585 DOI: 10.1128/AAC.00315-15  0.56
2015 Wainberg MA. Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 60: 1550-1. PMID 25681379 DOI: 10.1093/cid/civ107  1
2015 Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg MA. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. Journal of Virology. 89: 4681-4. PMID 25653436 DOI: 10.1128/JVI.03485-14  0.4
2015 Wares M, Hassounah S, Mesplède T, Sandstrom PA, Wainberg MA. Simian-tropic HIV as a model to study drug resistance against integrase inhibitors. Antimicrobial Agents and Chemotherapy. 59: 1942-9. PMID 25583721 DOI: 10.1128/AAC.04829-14  1
2015 Kramer VG, Hassounah S, Colby-Germinario SP, Oliveira M, Lefebvre E, Mesplède T, Wainberg MA. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. The Journal of Antimicrobial Chemotherapy. 70: 750-6. PMID 25433008 DOI: 10.1093/jac/dku451  0.56
2015 Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. The Journal of Antimicrobial Chemotherapy. 70: 405-11. PMID 25281399 DOI: 10.1093/jac/dku387  1
2015 Kramer VG, Wainberg MA. Resistance against inhibitors of HIV-1 entry into target cells Future Virology. 10: 97-112. DOI: 10.2217/fvl.14.104  1
2014 Wainberg MA, Lever AM. How will the ebola crisis impact the HIV epidemic? Retrovirology. 11: 110. PMID 25472763 DOI: 10.1186/s12977-014-0110-z  1
2014 Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, Hardy I, Moisi D, Lo E, Baril JG, Wainberg MA, Roger M, Tremblay C. A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load. Plos One. 9: e109420. PMID 25295725 DOI: 10.1371/journal.pone.0109420  1
2014 Quan Y, Xu H, Kramer VG, Han Y, Sloan RD, Wainberg MA. Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines. Virology Journal. 11: 177. PMID 25287969 DOI: 10.1186/1743-422X-11-177  0.56
2014 Bastarache SM, Mesplède T, Donahue DA, Sloan RD, Wainberg MA. Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency. Viruses. 6: 3487-99. PMID 25243372 DOI: 10.3390/v6093487  0.48
2014 Depatureaux A, Quashie PK, Mesplède T, Han Y, Koubi H, Plantier JC, Oliveira M, Moisi D, Brenner B, Wainberg MA. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase. Antimicrobial Agents and Chemotherapy. 58: 7141-50. PMID 25224008 DOI: 10.1128/AAC.03819-14  0.4
2014 Martin E, Carlson JM, Le AQ, Chopera DR, McGovern R, Rahman MA, Ng C, Jessen H, Kelleher AD, Markowitz M, Allen TM, Milloy MJ, Carrington M, Wainberg MA, Brumme ZL. Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology. 11: 64. PMID 25212686 DOI: 10.1186/s12977-014-0064-1  1
2014 Mesplède T, Wainberg MA. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses. 6: 3377-85. PMID 25166745 DOI: 10.3390/v6093377  1
2014 Bhargava M, Cajas JM, Wainberg MA, Klein MB, Pant Pai N. Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. Journal of the International Aids Society. 17: 18944. PMID 24998532 DOI: 10.7448/IAS.17.1.18944  1
2014 Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. Journal of Virology. 88: 9683-92. PMID 24920794 DOI: 10.1128/JVI.00947-14  1
2014 Kramer VG, Varsaneux O, Oliviera M, Colby-Germinario SP, Mesplède T, Wainberg MA. Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 7-14. PMID 24872133 DOI: 10.1097/QAI.0000000000000223  0.56
2014 Xu HT, Colby-Germinario SP, Oliveira M, Rajotte D, Bethell R, Wainberg MA. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 58: 4515-26. PMID 24867966 DOI: 10.1128/AAC.02729-14  0.56
2014 Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon efavirenz for first-line antiretroviral therapy? The Journal of Antimicrobial Chemotherapy. 69: 1742-7. PMID 24603962 DOI: 10.1093/jac/dku058  1
2014 Oliveira M, Mesplède T, Quashie PK, Moïsi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. Aids (London, England). 28: 813-9. PMID 24463394 DOI: 10.1097/QAD.0000000000000199  0.4
2014 Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. Aids (London, England). 28: 317-23. PMID 24326355 DOI: 10.1097/QAD.0000000000000168  1
2014 Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity. Journal of Virology. 88: 1536-47. PMID 24227862 DOI: 10.1128/JVI.02904-13  0.56
2014 Quan Y, Xu H, Wainberg MA. Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV. The Journal of Antimicrobial Chemotherapy. 69: 21-7. PMID 23963235 DOI: 10.1093/jac/dkt326  0.56
2013 Wainberg MA, Lever A. World AIDS Day: together we will stop HIV transmission and conquer AIDS. Retrovirology. 10: 129. PMID 24229411 DOI: 10.1186/1742-4690-10-129  1
2013 Quashie PK, Mesplède T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrobial Agents and Chemotherapy. 57: 6223-35. PMID 24080645 DOI: 10.1128/AAC.01835-13  0.48
2013 Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, Petropoulos CJ, Wainberg MA. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 57: 5649-57. PMID 24002090 DOI: 10.1128/AAC.01536-13  1
2013 Heredia A, Davis CE, Reitz MS, Le NM, Wainberg MA, Foulke JS, Wang LX, Redfield RR. Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1. The Journal of Infectious Diseases. 208: 2085-94. PMID 23922365 DOI: 10.1093/infdis/jit395  1
2013 Brenner B, Wainberg MA, Roger M. Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. Aids (London, England). 27: 1045-57. PMID 23902920 DOI: 10.1097/QAD.0b013e32835cffd9  1
2013 McCallum M, Oliveira M, Ibanescu RI, Kramer VG, Moisi D, Asahchop EL, Brenner BG, Harrigan PR, Xu H, Wainberg MA. Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 57: 4681-8. PMID 23856772 DOI: 10.1128/AAC.01029-13  0.56
2013 Donahue DA, Bastarache SM, Sloan RD, Wainberg MA. Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses. Journal of Virology. 87: 9620-32. PMID 23804632 DOI: 10.1128/JVI.01165-13  0.48
2013 Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. Journal of Acquired Immune Deficiency Syndromes (1999). 63: S248-54. PMID 23764643 DOI: 10.1097/QAI.0b013e3182986f96  1
2013 Invernizzi CF, Coutsinos D, Oliveira M, Schildknecht RS, Xu H, Gaseitsiwe S, Moisi D, Brenner BG, Wainberg MA. The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites. The Journal of Antimicrobial Chemotherapy. 68: 2192-6. PMID 23749954 DOI: 10.1093/jac/dkt204  0.56
2013 Lisovsky I, Schader SM, Sloan RD, Oliveira M, Coutsinos D, Bernard NF, Wainberg MA. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction. Intervirology. 56: 258-64. PMID 23689841 DOI: 10.1159/000348513  1
2013 Sloan RD, Kuhl BD, Mesplède T, Münch J, Donahue DA, Wainberg MA. Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. Journal of Virology. 87: 8110-23. PMID 23678185 DOI: 10.1128/JVI.00815-13  0.48
2013 Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrobial Agents and Chemotherapy. 57: 3100-9. PMID 23612196 DOI: 10.1128/AAC.00348-13  1
2013 Han YS, Xiao WL, Quashie PK, Mesplède T, Xu H, Deprez E, Delelis O, Pu JX, Sun HD, Wainberg MA. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Research. 98: 441-8. PMID 23583286 DOI: 10.1016/j.antiviral.2013.04.001  0.56
2013 Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 10: 22. PMID 23432922 DOI: 10.1186/1742-4690-10-22  1
2013 Sloan RD, Wainberg MA. Harnessing the therapeutic potential of host antiviral restriction factors that target HIV. Expert Review of Anti-Infective Therapy. 11: 1-4. PMID 23428096 DOI: 10.1586/eri.12.146  1
2013 Wainberg MA. Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. Hiv/Aids (Auckland, N.Z.). 5: 41-9. PMID 23413112 DOI: 10.2147/HIV.S32377  1
2013 Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 10: 11. PMID 23375003 DOI: 10.1186/1742-4690-10-11  1
2013 Parsons MS, Center RJ, Routy JP, Rouleau D, Leblanc R, Wainberg MA, Tremblay CL, Zannou MD, Kent SJ, Grant MD, Bernard NF. Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire. Aids Research and Human Retroviruses. 29: 778-83. PMID 23265432 DOI: 10.1089/AID.2012.0094  1
2013 Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. Aids (London, England). 27: 879-87. PMID 23262501 DOI: 10.1097/QAD.0b013e32835d9f6d  0.56
2013 Zaharatos GJ, Wainberg MA. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Annals of Medicine. 45: 236-41. PMID 23157601 DOI: 10.3109/07853890.2012.732704  1
2013 Asahchop EL, Oliveira M, Quashie PK, Moisi D, Martinez-Cajas JL, Brenner BG, Tremblay CL, Wainberg MA. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor. The Journal of Antimicrobial Chemotherapy. 68: 105-12. PMID 22945918 DOI: 10.1093/jac/dks342  0.48
2013 Spira SC, Wainberg MA. HIV vaccine triage: Halakhic considerations The Jewish Law Annual: Volume Twenty. 235-278. DOI: 10.4324/9780203714201  1
2013 Raffi F, Wainberg MA. Antiretroviral therapy with integrase inhibitors: More options Virologie. 17: 54-60. DOI: 10.1684/vir.2013.0479  1
2012 Raffi F, Wainberg MA. Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology. 9: 110. PMID 23253887 DOI: 10.1186/1742-4690-9-110  1
2012 Lamarre D, Wainberg MA. Staying ahead of viruses: a never ending task. Current Opinion in Virology. 2: 569-71. PMID 23025913 DOI: 10.1016/j.coviro.2012.09.002  1
2012 Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, Han Y, Quan Y, Wainberg MA. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase. Journal of Virology. 86: 12983-90. PMID 22993165 DOI: 10.1128/JVI.02005-12  0.52
2012 Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, et al. Biochemical mechanism of HIV-1 resistance to rilpivirine. The Journal of Biological Chemistry. 287: 38110-23. PMID 22955279 DOI: 10.1074/jbc.M112.398180  1
2012 Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacological Reviews. 64: 803-33. PMID 22759796 DOI: 10.1124/pr.111.005553  1
2012 Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 56: 5000-8. PMID 22733071 DOI: 10.1128/AAC.00591-12  0.48
2012 Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. Journal of Virology. 86: 8422-31. PMID 22623801 DOI: 10.1128/JVI.00271-12  0.52
2012 Schader SM, Colby-Germinario SP, Quashie PK, Oliveira M, Ibanescu RI, Moisi D, Mespléde T, Wainberg MA. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrobial Agents and Chemotherapy. 56: 4257-67. PMID 22615295 DOI: 10.1128/AAC.00639-12  1
2012 Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrobial Agents and Chemotherapy. 56: 4154-60. PMID 22615275 DOI: 10.1128/AAC.00409-12  1
2012 Han YS, Quashie P, Mesplede T, Xu H, Mekhssian K, Fenwick C, Wainberg MA. A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence. Journal of Virological Methods. 184: 34-40. PMID 22584270 DOI: 10.1016/j.jviromet.2012.05.003  0.56
2012 Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. Bmc Medicine. 10: 34. PMID 22498430 DOI: 10.1186/1741-7015-10-34  0.48
2012 Heidari S, Abdool Karim Q, Auerbach JD, Buitendijk SE, Cahn P, Curno MJ, Hankins C, Katabira E, Kippax S, Marlink R, Marsh J, Marusic A, Nass HM, Montaner J, Pollitzer E, ... ... Wainberg MA, et al. Gender-sensitive reporting in medical research. Journal of the International Aids Society. 15: 11. PMID 22400977 DOI: 10.1186/1758-2652-15-11  1
2012 Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, Wainberg MA. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrobial Agents and Chemotherapy. 56: 751-6. PMID 22123692 DOI: 10.1128/AAC.05821-11  1
2011 Whitney JB, Lim SY, Wainberg MA. Evolutionary mechanisms of retroviral persistence. Aids Reviews. 13: 234-9. PMID 21975359  1
2011 Wainberg MA, Cohen EA. Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence. Retrovirology. 8: 59. PMID 21767377 DOI: 10.1186/1742-4690-8-59  1
2011 Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection Retrovirology. 8. PMID 21722380 DOI: 10.1186/1742-4690-8-52  1
2011 Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. Aids (London, England). 25: 1585-94. PMID 21633286 DOI: 10.1097/QAD.0b013e3283491f89  1
2011 Wainberg MA, Jeang KT. XMRV as a human pathogen? Cell Host and Microbe. 9: 260-262. PMID 21501825 DOI: 10.1016/j.chom.2011.04.001  1
2011 Wainberg MA. AIDS: Drugs that prevent HIV infection Nature. 469: 306-307. PMID 21248832 DOI: 10.1038/469306a  1
2011 Roldan A, Liang C, Wainberg MA. Structural changes in the SL5 and SL6 leader sequences of HIV-1 RNA following interactions with the viral mGag protein Virus Research. 155: 98-105. PMID 20851722 DOI: 10.1016/j.virusres.2010.09.005  1
2011 Wainberg MA, Field HJ. Proof of principle: Antiretroviral drugs can prevent sexual transmission of HIV-1 Future Virology. 6: 549-551. DOI: 10.2217/fvl.11.37  1
2011 Field HJ, Wainberg MA. Editorial: Antiviral drug development Future Virology. 6: 545-547. DOI: 10.2217/fvl.11.36  1
2011 Schader SM, Wainberg MA. Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future Hiv and Aids Review. 10: 91-98. DOI: 10.1016/j.hivar.2011.09.003  1
2010 Lisovsky I, Schader SM, Martinez-Cajas JL, Oliveira M, Moisi D, Wainberg MA. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrobial Agents and Chemotherapy. 54: 2878-85. PMID 20404123 DOI: 10.1128/AAC.01828-09  1
2010 Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrobial Agents and Chemotherapy. 54: 2401-8. PMID 20308384 DOI: 10.1128/AAC.01795-09  1
2010 Wainberg MA, Albert J. Can the further clinical development of bevirimat be justified? Aids. 24: 773-774. PMID 20154583 DOI: 10.1097/QAD.0b013e328331c83b  1
2010 Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrobial Agents and Chemotherapy. 54: 1047-54. PMID 20038621 DOI: 10.1128/AAC.01537-09  1
2010 Cahn P, Wainberg MA. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine The Journal of Antimicrobial Chemotherapy. 65: 213-217. PMID 20007333 DOI: 10.1093/jac/dkp422  1
2010 Wainberg MA, Brenner BG. Role of HIV subtype diversity in the development of resistance to antiviral drugs Viruses. 2: 2493-2508. DOI: 10.3390/v2112493  1
2009 Wainberg MA. Two standards of care for HIV: Why are Africans being short-changed? Retrovirology. 6. PMID 19951412 DOI: 10.1186/1742-4690-6-109  1
2009 Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrobial Agents and Chemotherapy. 53: 4667-72. PMID 19704127 DOI: 10.1128/AAC.00800-09  1
2009 Rong L, Zhang J, Lu J, Pan Q, Lorgeoux RP, Aloysius C, Guo F, Liu SL, Wainberg MA, Liang C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. Journal of Virology. 83: 7536-46. PMID 19474106 DOI: 10.1128/JVI.00620-09  0.52
2009 Wainberg MA. Criminalizing HIV transmission may be a mistake Cmaj. 180: 688. PMID 19289817 DOI: 10.1503/cmaj.090249  1
2009 Wainberg MA. New findings on blockage of HIV-1 RNase H activity Aids. 23: 223-224. PMID 19098492 DOI: 10.1097/QAD.0b013e32831c5526  1
2009 Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection Methods in Molecular Biology. 485: 427-433. PMID 19020842 DOI: 10.1007/978-1-59745-170-3_29  1
2009 Wainberg MA. Perspectives on antiviral drug development Antiviral Research. 81: 1-5. PMID 18948140 DOI: 10.1016/j.antiviral.2008.09.003  1
2008 Wainberg MA. HIV transmission should be decriminalized: HIV prevention programs depend on it Retrovirology. 5. PMID 19046412 DOI: 10.1186/1742-4690-5-108  1
2008 Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries. Journal of the International Aids Society. 11: 2. PMID 19014657 DOI: 10.1186/1758-2652-11-2  0.96
2008 Wainberg MA, Jeang KT. 25 years of HIV-1 research - Progress and perspectives Bmc Medicine. 6. PMID 18976462 DOI: 10.1186/1741-7015-6-31  1
2008 Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. The impact of the journalist-to-journalist program on worldwide HIV awareness. Aids (London, England). 22: 1687-8. PMID 18670235 DOI: 10.1097/QAD.0b013e328308de21  1
2008 Wainberg MA, Petrella M. Development and Transmission of HIV Drug Resistance Global Hiv/Aids Medicine. 149-159. DOI: 10.1016/B978-1-4160-2882-6.50018-6  1
2007 Gayle H, Wainberg MA. The 16th International Conference on AIDS: Will it leave a legacy? Medgenmed Medscape General Medicine. 9. PMID 17955071  1
2007 Wainberg MA, Clotet B. Immunologic response to protease inhibitor-based highly active antiretroviral therapy: A review Aids Patient Care and Stds. 21: 609-620. PMID 17919088 DOI: 10.1089/apc.2006.0176  1
2007 Whitney JB, Wainberg MA. Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome. Retrovirology. 4: 44. PMID 17608929 DOI: 10.1186/1742-4690-4-44  1
2007 Gayle H, Wainberg MA. Impact of the 16th International Conference on AIDS: Can these conferences lead to policy change? Retrovirology. 4. PMID 17288591 DOI: 10.1186/1742-4690-4-13  1
2007 Schapiro J, Wainberg MA. Editorial introductions Current Opinion in Hiv and Aids. 2. DOI: 10.1097/01.COH.0000259656.58358.4d  1
2006 Wainberg MA. Twenty-five years of AIDS: Where are we now? Medgenmed Medscape General Medicine. 8. PMID 17415304  1
2006 Whitney JB, Wainberg MA. Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239. Retrovirology. 3: 96. PMID 17184529 DOI: 10.1186/1742-4690-3-96  1
2006 Wainberg MA. The need to promote public health in the field of illicit drug use Cmaj. 175: 1395-1396. PMID 17116908 DOI: 10.1503/cmaj.061404  1
2006 Grant RM, Wainberg MA. Chemoprophylaxis of HIV infection: Moving forward with caution Journal of Infectious Diseases. 194: 874-876. PMID 16960773 DOI: 10.1086/507314  1
2006 Turner D, Wainberg MA. HIV transmission and primary drug resistance Aids Reviews. 8: 17-23. PMID 16736948  1
2006 Wainberg MA. The XVI International Conference on AIDS: The place to be! Retrovirology. 3. PMID 16457720 DOI: 10.1186/1742-4690-3-9  1
2005 Wainberg MA. Generic HIV drugs - Enlightened policy for global health New England Journal of Medicine. 352: 747-750. PMID 15728804 DOI: 10.1056/NEJMp048356  1
2004 Wainberg MA. eJIAS: Editor's Welcome Medgenmed : Medscape General Medicine. 6: 58. PMID 15520682  1
2004 Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness Expert Review of Anti-Infective Therapy. 2: 147-151. PMID 15482179  1
2004 Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance Aids. 18. PMID 15322487 DOI: 10.1097/00002030-200406003-00012  1
2004 Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options Journal of Acquired Immune Deficiency Syndromes. 37. PMID 15319668  1
2004 Wainberg MA. The emergence of HIV resistance and new antiretrovirals: Are we winning? Drug Resistance Updates. 7: 163-167. PMID 15296858 DOI: 10.1016/j.drup.2004.06.001  1
2004 Spira SC, Wainberg MA. Jewish religious ethics mandate access to antiretroviral drugs in developing countries Journal of the International Association of Physicians in Aids Care. 3: 7-11. PMID 15112418 DOI: 10.1177/154510970400300102  1
2004 Wainberg MA. Is there any hope for AIDS? Clinical and Investigative Medicine. 27: 51-58. PMID 15061586  1
2004 Wainberg MA. eJIAS: Editorial welcome Medgenmed Medscape General Medicine. 6.  1
2004 Hsu RK, Wainberg MA. Do New Protease Inhibitors Offer Improved Sequencing Options? Issues of PI Resistance and Sequencing Journal of Acquired Immune Deficiency Syndromes. 35.  1
2003 Diallo K, Götte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 47: 3377-83. PMID 14576091 DOI: 10.1128/AAC.47.11.3377-3383.2003  1
2003 Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors Journal of Acquired Immune Deficiency Syndromes. 34. PMID 14562852 DOI: 10.1097/00126334-200309011-00002  1
2003 Rong L, Russell RS, Hu J, Laughrea M, Wainberg MA, Liang C. Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1. Virology. 314: 221-8. PMID 14517075  0.52
2003 Youle M, Wainberg MA. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? [4] Aids. 17: 937-938. PMID 12660549 DOI: 10.1097/00002030-200304110-00027  1
2003 Xie B, Wainberg MA, Frankel AD. Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions. Journal of Virology. 77: 1984-91. PMID 12525632 DOI: 10.1128/JVI.77.3.1984-1991.2003  1
2003 Liang C, Hu J, Whitney JB, Kleiman L, Wainberg MA. A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1. Journal of Virology. 77: 1772-83. PMID 12525611 DOI: 10.1128/JVI.77.3.1772-1783.2003  1
2003 Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy Journal of the International Association of Physicians in Aids Care. 2: 102-105. DOI: 10.1177/154510970300200302  1
2003 Wainberg MA. HIV DART 2002: Frontiers in drug development for antiretroviral therapies: 15-19 December 2002, Naples, FL, USA Idrugs. 6: 110-113.  1
2002 Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? Aids Reviews. 4: 224-232. PMID 12555696  1
2002 Brenner BG, Turner D, Wainberg MA. HIV-1 drug resistance: Can we overcome? Expert Opinion On Biological Therapy. 2: 751-761. PMID 12387674 DOI: 10.1517/14712598.2.7.751  1
2002 Whitney JB, Oliveira M, Detorio M, Guan Y, Wainberg MA. The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus. Journal of Virology. 76: 8958-62. PMID 12163615 DOI: 10.1128/JVI.76.17.8958-8962.2002  1
2002 Liang C, Wainberg MA. The role of Tat in HIV-1 replication: An activator and/or a suppressor? Aids Reviews. 4: 41-49. PMID 11998784  1
2002 Khorchid A, Halwani R, Wainberg MA, Kleiman L. Role of RNA in facilitating Gag/Gag-Pol interaction. Journal of Virology. 76: 4131-7. PMID 11907255 DOI: 10.1128/JVI.76.8.4131-4137.2002  1
2002 Kameoka M, Morgan M, Binette M, Russell RS, Rong L, Guo X, Mouland A, Kleiman L, Liang C, Wainberg MA. The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. Journal of Virology. 76: 3637-45. PMID 11907203  0.52
2002 Brulé F, Marquet R, Rong L, Wainberg MA, Roques BP, Le Grice SF, Ehresmann B, Ehresmann C. Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex. Rna (New York, N.Y.). 8: 8-15. PMID 11873759  0.52
2002 Whitney JB, Wainberg MA. Isoniazid, the frontline of resistance in mycobacterium tuberculosis McGill Journal of Medicine. 6: 114-123.  1
2001 Guan Y, Diallo K, Whitney JB, Liang C, Wainberg MA. An intact U5-leader stem is important for efficient replication of simian immunodeficiency virus. Journal of Virology. 75: 11924-9. PMID 11689678 DOI: 10.1128/JVI.75.23.11924-11929.2001  1
2001 Guan Y, Diallo K, Detorio M, Whitney JB, Liang C, Wainberg MA. Partial restoration of replication of simian immunodeficiency virus by point mutations in either the dimerization initiation site (DIS) or Gag region after deletion mutagenesis within the DIS. Journal of Virology. 75: 11920-3. PMID 11689677 DOI: 10.1128/JVI.75.23.11920-11923.2001  1
2001 Wainberg MA, White AJ. Current insights into reverse transcriptase inhibitor-associated resistance Antiviral Therapy. 6: 11-19. PMID 11678474  1
2001 Rong L, Liang C, Hsu M, Guo X, Roques BP, Wainberg MA. HIV-1 nucleocapsid protein and the secondary structure of the binary complex formed between tRNA(Lys.3) and viral RNA template play different roles during initiation of (-) strand DNA reverse transcription. The Journal of Biological Chemistry. 276: 47725-32. PMID 11602578 DOI: 10.1074/jbc.M105124200  0.52
2001 Rong L, Russell RS, Hu J, Guan Y, Kleiman L, Liang C, Wainberg MA. Hydrophobic amino acids in the human immunodeficiency virus type 1 p2 and nucleocapsid proteins can contribute to the rescue of deleted viral RNA packaging signals. Journal of Virology. 75: 7230-43. PMID 11461996 DOI: 10.1128/JVI.75.16.7230-7243.2001  0.52
2001 Guan Y, Whitney JB, Detorio M, Wainberg MA. Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted. Journal of Virology. 75: 4056-67. PMID 11287555 DOI: 10.1128/JVI.75.9.4056-4067.2001  1
2001 Wainberg MA. Microbicides 2000 conference. Welcoming remarks. The global need for microbicides Aids. 15. PMID 11228106  1
2001 Guan Y, Whitney JB, Liang C, Wainberg MA. Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences. Journal of Virology. 75: 2776-85. PMID 11222701 DOI: 10.1128/JVI.75.6.2776-2785.2001  1
2001 Kameoka M, Rong L, Götte M, Liang C, Russell RS, Wainberg MA. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. Journal of Virology. 75: 2675-83. PMID 11222691 DOI: 10.1128/JVI.75.6.2675-2683.2001  0.52
2001 Wainberg MA, Youle M. Can we protect high-risk populations against HIV infection through use of antiviral drugs? A proposal for once-daily pre-exposure prophylaxis of HIV disease International Antiviral News. 9: 184-185.  1
2000 Götte M, Wainberg MA. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 3: 30-38. PMID 11498363 DOI: 10.1054/drup.2000.0126  1
2000 Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission of HIV-1 infection Annals of the New York Academy of Sciences. 918: 9-15. PMID 11131739  1
2000 Cen S, Khorchid A, Gabor J, Rong L, Wainberg MA, Kleiman L. Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1. Journal of Virology. 74: 10796-800. PMID 11044125 DOI: 10.1128/JVI.74.22.10796-10800.2000  1
2000 Guan Y, Whitney JB, Diallo K, Wainberg MA. Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus. Journal of Virology. 74: 8854-60. PMID 10982327 DOI: 10.1128/JVI.74.19.8854-8860.2000  1
2000 Wei X, Götte M, Wainberg MA. Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers Nucleic Acids Research. 28: 3065-3074. PMID 10931921  1
2000 Liang C, Rong L, Russell RS, Wainberg MA. Deletion mutagenesis downstream of the 5' long terminal repeat of human immunodeficiency virus type 1 is compensated for by point mutations in both the U5 region and gag gene. Journal of Virology. 74: 6251-61. PMID 10864634  0.52
2000 Hsu M, Wainberg MA. Interactions between human immunodeficiency virus type 1 reverse transcriptase, tRNA primer, and nucleocapsid protein during reverse transcription Journal of Human Virology. 3: 16-26. PMID 10774803  1
2000 Hsu M, Rong L, de Rocquigny H, Roques BP, Wainberg MA. The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions. Nucleic Acids Research. 28: 1724-9. PMID 10734191  0.52
1999 Wainberg MA, Kallings LO. The International Conference on AIDS. Why we chose South Africa Aids (London, England). 13: 11-12. PMID 10449276  1
1999 Liang C, Rong L, Quan Y, Laughrea M, Kleiman L, Wainberg MA. Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site. Journal of Virology. 73: 7014-20. PMID 10400801  0.52
1999 Quan Y, Rong L, Liang C, Wainberg MA. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. Journal of Virology. 73: 6700-7. PMID 10400767  0.52
1999 Wainberg MA. A new source of resistance to HIV drugs Journal of the American Medical Association. 281: 2169-2170. PMID 10376549 DOI: 10.1001/jama.281.23.2169  1
1999 Wainberg MA. South Africa must admit that HIV/AIDS is its greatest enemy [13] British Medical Journal. 318: 1700. PMID 10373193  1
1999 Liang C, Rong L, Cherry E, Kleiman L, Laughrea M, Wainberg MA. Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. Journal of Virology. 73: 6147-51. PMID 10364374  0.52
1999 Götte M, Li X, Wainberg MA. HIV-1 reverse transcription: A brief overview focused on structure- function relationships among molecules involved in initiation of the reaction Archives of Biochemistry and Biophysics. 365: 199-210. PMID 10328813 DOI: 10.1006/abbi.1999.1209  1
1999 Brenner BG, Wainberg MA. Heat shock protein-based therapeutic strategies against human immunodeficiency virus type I infection Infectious Diseases in Obstetrics and Gynecology. 7: 80-90. PMID 10231014  1
1999 Wainberg MA. Say no to boycott of AIDS conference [1] Nature. 398: 555. PMID 10217133  1
1999 Wainberg MA. The need for microbicides: Why aren't women's groups more involved in the fight against AIDS? Aids Research and Human Retroviruses. 15: 405-406. PMID 10195749 DOI: 10.1089/088922299311141  1
1999 Wainberg MA. Hope and despair: New drug development versus transmission of drug-resistant forms of HIV-I International Antiviral News. 7: 89-97.  1
1999 Wainberg MA. Drug Therapy in HIV infection - Fourth International Congress Idrugs. 2: 18-19.  1
1999 Wainberg MA. Problems associated with human immunodeficiency virus resistance to antiviral drugs McGill Journal of Medicine. 5: 54-59.  1
1999 Gotte M, Wainberg MA. Rescue of chain-terminated DNA synthesis: A novel concept to explain HIV resistance to zidovudine International Antiviral News. 7: 121.  1
1999 Wainberg MA, Kallings LO. The International Conference on AIDS: Why we chose South Africa Aids. 13.  1
1998 Wainberg MA. Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase Antiviral Therapy. 3: 177-182. PMID 10682135  1
1998 Ungvarski PJ, Wainberg MA, Friedland G. Improving patient compliance with HIV treatment regimens (multiple letters) [3] Journal of the American Medical Association. 280: 1745-1746. PMID 9842947  1
1998 Friedman SR, Wainberg MA, Drucker E. Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications. Aids (London, England). 12: 2089-93. PMID 9833849 DOI: 10.1097/00002030-199816000-00003  1
1998 Cherry E, Liang C, Rong L, Quan Y, Inouye P, Li X, Morin N, Kotler M, Wainberg MA. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. Journal of Molecular Biology. 284: 43-56. PMID 9811541 DOI: 10.1006/jmbi.1998.1968  0.52
1998 Rong L, Liang C, Hsu M, Kleiman L, Petitjean P, de Rocquigny H, Roques BP, Wainberg MA. Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA. Journal of Virology. 72: 9353-8. PMID 9765488  0.52
1998 Quan Y, Inouye P, Liang C, Rong L, Götte M, Wainberg MA. Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing. The Journal of Biological Chemistry. 273: 21918-25. PMID 9705331  0.52
1998 Liang C, Rong L, Götte M, Li X, Quan Y, Kleiman L, Wainberg MA. Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription. The Journal of Biological Chemistry. 273: 21309-15. PMID 9694891  0.52
1998 Cherry E, Morin N, Wainberg MA. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication Aids. 12: 967-975. PMID 9662192 DOI: 10.1097/00002030-199809000-00002  1
1998 Liang C, Rong L, Laughrea M, Kleiman L, Wainberg MA. Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication. Journal of Virology. 72: 6629-36. PMID 9658109  0.52
1998 Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance Journal of the American Medical Association. 279: 1977-1983. PMID 9643862 DOI: 10.1001/jama.279.24.1977  1
1998 Wainberg MA, Cameron DW. HIV resistance to antiviral drugs: public health implications Drug Resistance Updates. 1: 104-108. DOI: 10.1016/S1368-7646(98)80025-3  1
1998 Wainberg MA, Montaner JSG. Emerging challenges in the clinical testing of new drugs for HIV disease International Antiviral News. 6: 224-226.  1
1997 Soudeyns H, Wainberg MA. Effects of RU486 on HIV-1 replication [2] Nature Medicine. 3: 1302-1303. PMID 9396582  1
1997 Liang C, Rong L, Morin N, Cherry E, Huang Y, Kleiman L, Wainberg MA. The roles of the human immunodeficiency virus type 1 Pol protein and the primer binding site in the placement of primer tRNA(3Lys) onto viral genomic RNA. Journal of Virology. 71: 9075-86. PMID 9371564  0.52
1997 Liang C, Li X, Rong L, Inouye P, Quan Y, Kleiman L, Wainberg MA. The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. Journal of Virology. 71: 5750-7. PMID 9223461  0.52
1997 Wainberg MA. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials Leukemia. 11: 85-88. PMID 9209307  1
1997 Li X, Quan Y, Wainberg MA. Controlling elements in replication of the human immunodeficiency virus type 1 Cellular and Molecular Biology (Noisy-Le-Grand, France). 43: 443-454. PMID 9193800  1
1997 Wainberg MA, Parniak MA. Is HIV resistance to 3TC of clinical benefit? International Antiviral News. 5: 3-5.  1
1996 Geleziunas R, Morin N, Wainberg MA. Mechanisms of reduction of CD4 receptor expression on the surface of HIV-1 infected cells Comptes Rendus De L'AcadéMie Des Sciences. SéRie Iii, Sciences De La Vie. 319: 653-662. PMID 8949388  1
1996 Arts EJ, Wainberg MA. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription Antimicrobial Agents and Chemotherapy. 40: 527-540. PMID 8851566  1
1996 Arts EJ, Wainberg MA. Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription Advances in Virus Research. 46: 97-163. PMID 8824699  1
1996 Merigan TC, Wainberg MA. Introduction Aids, Supplement. 10: S1.  1
1995 Bour S, Geleziunas R, Wainberg MA. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection Microbiological Reviews. 59: 63-93. PMID 7708013  1
1995 Mercure L, Phaneuf D, Wainberg MA. Differential effect of the immunomodulatory hormone somatostatin on replication of human immunodeficiency virus type 1 in CD4+ and CD8+ T lymphocytes Clinical and Diagnostic Laboratory Immunology. 2: 192-198. PMID 7697528  1
1995 Wainberg MA, Gu Z. Targeting hiv reverse transcriptase in novel ways Nature Medicine. 1: 628-629. PMID 7585138 DOI: 10.1038/nm0795-628  1
1995 Germinario RJ, DeSantis T, Wainberg MA. Insulin-like growth factor 1 and insulin inhibit HIV type 1 replication in cultured cells Aids Research and Human Retroviruses. 11: 555-561. PMID 7576911  1
1995 Arts EJ, Li Z, Wainberg MA. Analysis of primer extension and the first template switch during human immunodeficiency virus reverse transcription Journal of Biomedical Science. 2: 314-321. DOI: 10.1007/BF02255218  1
1994 Brenner BG, Gornitsky M, Wainberg MA. Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS Clinical and Diagnostic Laboratory Immunology. 1: 538-544. PMID 8556498  1
1994 Geleziunas R, Bour S, Wainberg MA. HIV-1 associated down-modulation of CD4 gene expression is differentially restricted in lymphocytic and monocytic cell lines Journal of Leukocyte Biology. 55: 589-595. PMID 8182337  1
1994 Brenner BG, Vo C, Wainberg MA. Different effects of breast cancer, HIV-1 infection and chemotherapy on inducible natural immunity Leukemia. 8. PMID 8152288  1
1994 Geleziunas R, Bour S, Wainberg MA. Correlation between high level gp160 expression and reduced CD4 biosynthesis in clonal derivatives of human immunodeficiency virus type 1-infected U-937 cells Journal of General Virology. 75: 857-865. PMID 8151301  1
1994 Mercure L, Wainberg MA. Direct involvement of extracellular HIV-1 virions in the apoptosis of CD8+ lymphocytes: A two-step model Medical Hypotheses. 42: 159-168. PMID 8057970 DOI: 10.1016/0306-9877(94)90093-0  1
1994 Geleziunas R, Bour S, Wainberg MA. Cell surface down-modulation of CD4 after infection by HIV-1 Faseb Journal. 8: 593-600. PMID 8005387  1
1994 Arts EJ, Wainberg MA. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription Antimicrobial Agents and Chemotherapy. 38: 1008-1016. PMID 7915097  1
1994 Bour S, Geleziunas R, Wainberg MA. The role of CD4 and its downmodulation in establishment and maintenance of HIV-1 infection Immunological Reviews. 147-171. PMID 7821926  1
1994 Geleziunas R, Bour S, Wainberg MA. Human immunodeficiency virus type 1-associated CD4 downmodulation Adv.Virus Res.. 44: 203-266. PMID 7817874  1
1994 Smith M, Salomon H, Wainberg MA. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1 Clinical and Investigative Medicine. 17: 226-243. PMID 7523016  1
1994 Wainberg MA. Foreword Leukemia. 8.  1
1993 Wainberg MA. Why are there so many myths about AIDS? Cmaj. 148: 745-746. PMID 8439932  1
1993 Mercure L, Phaneuf LD, Wainberg MA. Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells Journal of General Virology. 74: 2077-2083. PMID 8409932  1
1993 Bentwich Z, Wainberg MA. Host immunity and the course of HIV infection Israel Journal of Medical Sciences. 29: 34-36. PMID 8244678  1
1993 Lalonde RG, Rene P, Wainberg MA. Opportunistic infections and CD4+ T-lymphocytopenia without HIV infection: Report of two cases Cmaj. 149: 179-182. PMID 8100736  1
1993 Wainberg MA, Geleziunas R, Bour S. The role and fate of the CD4 molecule in lymphocytes and monocytes infected by HIV-1 Brazilian Journal of Medical and Biological Research. 26: 123-136. PMID 7504965  1
1992 Baruchel S, Wainberg MA. The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus Journal of Leukocyte Biology. 52: 111-114. PMID 1640166  1
1992 Wainberg MA, Margolese RG. Strategies in the treatment of AIDS and related diseases: The lessons of cancer chemotherapy: New drugs Cancer Investigation. 10: 143-153. PMID 1551024 DOI: 10.3109/07357909209032775  1
1992 Tremblay M, Rooke R, Wainberg MA. Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: In vitro studies evaluating level of replication-competent viruses and cytopathogenicity Aids. 6: 1445-1449. PMID 1492930  1
1992 D'Addario M, Wainberg MA, Hiscott J. Activation of cytokine genes in HIV-1 infected myelomonoblastic cells by phorbol ester and tumor necrosis factor. Journal of Immunology (Baltimore, Md. : 1950). 148: 1222-9. PMID 1371135  1
1992 Geleziunas R, Schipper HM, Wainberg MA. Pathogenesis and therapy of HIV-1 infection of the central nervous system Aids. 6: 1411-1426. PMID 1337255  1
1991 Wainberg MA, Schechter MT. AIDS research funding in Canada: Future directions and government policy Cmaj. 144: 651-653. PMID 1998924  1
1991 Bour S, Boulerice F, Wainberg MA. Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type Journal of Virology. 65: 6387-6396. PMID 1942241  1
1991 Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases Journal of Leukocyte Biology. 50: 628-640. PMID 1940615  1
1991 Yao XJ, Wainberg MA, Pollak M. The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin [4] Aids. 5: 1389-1391. PMID 1768390  1
1990 Tremblay M, Wainberg MA. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera Journal of Infectious Diseases. 162: 735-737. PMID 2387997 DOI: 10.1093/infdis/162.3.735  1
1990 D'Addario M, Roulston A, Wainberg MA, Hiscott J. Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells. Journal of Virology. 64: 6080-9. PMID 2243388  1
1990 Boulerice F, Wainberg MA. Inhibition of AZT of HIV-1 replication in acutely infected U-937 cells Journal of Leukocyte Biology. 47: 498-505. PMID 2191063  1
1990 Rooke R, Tremblay M, Wainberg MA. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells Virology. 176: 205-215. PMID 1691885 DOI: 10.1016/0042-6822(90)90245-M  1
1989 Numazaki K, Wainberg MA, McDonald J. Chlamydia trachomatis infections in infants Cmaj. 140: 615-622. PMID 2645987  1
1989 Tremblay M, Gornitsky M, Wainberg MA. Active replication of human immunodeficiency virus type 1 by peripheral blood mononuclear cells following coincubation with herpes viruses Journal of Medical Virology. 29: 109-114. PMID 2557380  1
1989 Tremblay M, Wainberg MA. Susceptibility to AZT of Hiv-1 Variants Grown in Epstein-Barr Virus-Transformed B Cell Lines Journal of Infectious Diseases. 160: 31-36. PMID 2543710 DOI: 10.1093/infdis/160.1.31  1
1989 Tremblay M, Wainberg MA. Susceptibility of EBV-carrying B cell lines to infection by HIV-1: variability of production of progeny virus and expression of viral antigens Cancer Letters. 48: 95-103. PMID 2479462 DOI: 10.1016/0304-3835(89)90043-8  1
1988 Wainberg MA, Kendall O, Gilmore N. Vaccine and antiviral strategies against infections caused by human immunodeficiency virus Cmaj. 138: 797-807. PMID 3282628  1
1988 Roy S, Wainberg MA. Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS) Journal of Leukocyte Biology. 43: 91-97. PMID 3275735  1
1988 Samnotra V, Germinario RJ, Wainberg MA. Presence of insulin binding sites on viral particles Antiviral Research. 9: 285-293. PMID 2851292 DOI: 10.1016/0166-3542(88)90024-1  1
1988 Tremblay M, Fitz-Gibbon L, Wainberg MA. Heterogeneity of HIV-1 replication and antigen expression in EBV-transformed B cell lines Leukemia. 2. PMID 2849000  1
1988 Numazaki K, Goldman H, Wainberg MA. Effect of co-incubation with cytomegalovirus on growth of interleukin 2-dependent lymphocytes Microbial Pathogenesis. 4: 137-144. PMID 2462156 DOI: 10.1016/0882-4010(88)90055-1  1
1987 Poulin L, Skalski V, Wainberg MA. Effect of Phorbol Ester on Growth of Tumors Induced by Rous Sarcoma Virus and on pp60src Kinase Activity in These Tumors Cancer Research. 47: 3637-3642. PMID 3036345  1
1987 Skalski V, Poulin L, Wainberg MA. Effect of phorbol myristate acetate on cultured tumor cells derived from different stages of avian sarcoma virus (ASV)-induced neoplastic growth Experimental Biology. 46: 223-229. PMID 3034659  1
1987 Wainberg MA, Skalski V, Poulin L. Differential effects of phorbol ester on tumor cells induced by avian sarcoma virus Anticancer Research. 7: 81-85. PMID 3032073  1
1987 Roy S, Portnoy J, Wainberg MA. Need for Caution in Interpretation of Western Blot Tests for HIV Jama: the Journal of the American Medical Association. 257: 1047. PMID 3027425 DOI: 10.1001/jama.1987.03390080037010  1
1987 Poulin L, Spira B, Wainberg MA. Studies on pp60(src) and associated kinase activity in regressing tumors induced by Rous sarcoma virus In Vivo. 1: 125-130. PMID 2856518  1
1987 Wainberg MA, Blain N, Fitz-Gibbon L. Differential susceptibility of human lymphocyte cultures to infection by HIV Clinical and Experimental Immunology. 70: 136-142. PMID 2826057  1
1987 Poulin L, Wainberg MA. Expression of avian sarcoma virus genes in tumor cells derived from different periods of tumor growth Microbial Pathogenesis. 2: 101-112. PMID 2467160 DOI: 10.1016/0882-4010(87)90102-1  1
1987 Wainberg MA, Bleau G. Effect of benzalkonium chloride on HIV and related infections and on other infectious agents Archives of Aids Research. 1: 57-68.  1
1986 Wainberg MA, Read SE. Public funding for AIDS research in Canada and the USA Canadian Medical Association Journal. 134: 109-110. PMID 3942910  1
1985 Margolese RG, Wainberg MA. Enhanced viral inhibition of lymphocyte mitogenesis in patients with advanced breast cancer Clinical and Experimental Immunology. 62: 85-94. PMID 2998661  1
1985 Wainberg MA, Mills EL. Mechanisms of virus-induced immune suppression. Canadian Medical Association Journal. 132: 1261-7. PMID 2986813  1
1985 Poulin L, Grise-Miron L, Wainberg MA. Immunological responsiveness against tumors induced by avian sarcoma virus: Reduced expression of pp60(src) kinase activity in regressing tumors Journal of Virology. 53: 800-806. PMID 2579245  1
1983 Wainberg MA, Poulin L. Alteration of phenotype of 'regressor' avian sarcoma cells following treatment with phorbol ester Cancer Letters. 19: 273-282. PMID 6309365 DOI: 10.1016/0304-3835(83)90095-2  1
1983 Wainberg MA, Vydelingum S, Margolese RG. Viral inhibition of lymphocyte mitogenesis: Interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same Journal of Immunology. 130: 2372-2378. PMID 6300245  1
1982 Wainberg MA, Israel E, Margolese RG. Further studies on the mitogenic and immune-modulating effects of plasminogen activator Immunology. 45: 715-720. PMID 6978286  1
1982 Wainberg MA, Germinario RJ. Phenotypic differences between tumor cells derived from different stages of neoplastic growth European Journal of Cancer and Clinical Oncology. 18: 545-551. PMID 6288392 DOI: 10.1016/0277-5379(82)90223-1  1
1982 Wainberg MA, Israel E. Immune stimulation of sensitized chicken lymphocytes by avian retrovirus proteins Journal of General Virology. 60: 391-395. PMID 6286858  1
1982 Wainberg MA, Margolese RG. The effects of T cell growth factor and virus purification on virus mediated inhibition of lymphocyte mitogenesis Clinical and Experimental Immunology. 48: 163-170. PMID 6282509  1
1982 Wainberg MA, Israel E, Yu M. Immune Selection of Tumor Cell Variants in Chickens Bearing Tumors Induced by Avian Sarcoma Virus Cancer Research. 42: 1669-1675. PMID 6279281  1
1981 Wainberg MA, Cohen SD. Studies on interactions between plasminogen activator-containing fluids and avian and murine lymphocytes Developmental and Comparative Immunology. 5: 649-660. PMID 6274714  1
1981 Israel E, Wainberg MA. Viral inhibition of lymphocyte mitogenesis: The role of macrophages as primary targets of virus-cell interaction Res Journal of the Reticuloendothelial Society. 29: 105-116. PMID 6260939  1
1980 Israel E, Beiss B, Wainberg MA. Viral abrogation of lymphocyte mitogenesis: induction of a soluble factor inhibitory to cellular proliferation Immunology. 40: 77-85. PMID 6448221  1
1980 Wainberg MA, Beiss B, Israel E. Virus-mediated abrogation of chicken lymphocyte responsiveness to mitogenic stimulus Avian Diseases. 24: 580-590. PMID 6255923  1
1980 Margolese RG, Israel E, Wainberg MA. Non-specific inhibition by virus particles of human lymphocyte mitogenesis Clinical and Experimental Immunology. 41: 243-251. PMID 6254707  1
1980 Rohan P, Wainberg MA. Effect of prior inoculation with chemical carcinogens on development of avian retrovirus-induced neoplasia in chickens British Journal of Cancer. 41: 130-135. PMID 6244845 DOI: 10.1038/bjc.1980.15  1
1980 Wainberg MA, Israel E. Viral inhibition of lymphocyte mitogenesis. I. Evidence for the nonspecificity of the effect Journal of Immunology. 124: 64-70. PMID 6243153  1
1979 Israel E, Yu M, Wainberg MA. Non-specific effects of avian retrovirus co-incubation on lymphocyte function: Abrogation of antigen- and mitogen-induced proliferative responsiveness Immunology. 38: 41-50. PMID 229075  1
1979 Mandeville R, Rohan P, Wainberg MA. Neutralization of pseudotypes of vesicular stomatitis virus by sera from avian retrovirus-infected hosts International Journal of Cancer. 23: 415-423. PMID 220198  1
1979 Wainberg MA, Yu M, Israel E. Decreased production of transforming virus and altered antigenic behaviour in cultured avian sarcoma cells Journal of General Virology. 42: 255-264. PMID 217955  1
1978 Wainberg MA, Israel E. Enhancement of avian sarcoma virus-induced tumor growth after pretreatment with BCG Infection and Immunity. 22: 328-333. PMID 215547  1
1978 Wainberg MA, Sauerwein H, Israel E. Immunological and structural properties of Rous sarcoma virus-transformed and tumor cells Revue Canadienne De Biologie. 37: 15-25. PMID 209500  1
1978 Israel E, Mandeville R, Wainberg MA. Effect of glucosamine on virus production and antigen expression in avian sarcoma virus-transformed cells Canadian Journal of Microbiology. 24: 1024-1031. PMID 81707  1
1977 Wainberg MA, Israël E, Schwartz-Luft E, Yu M. Differential Expression of Relevant Rous Sarcoma-associated Antigens in Cultured Cells Cancer Research. 37: 3026-3033. PMID 195716  1
1977 Israel E, Wainberg MA. Development of cellular anti-tumor immunity in chickens bearing tumors induced by Rous sarcoma virus Journal of Immunology. 118: 2237-2242. PMID 193994  1
1977 Wainberg MA, Margolese RG. Desensitization of effective anti-tumour immunity in guinea pigs European Journal of Cancer (1965). 13: 131-137. PMID 192557 DOI: 10.1016/0014-2964(77)90191-8  1
1977 Wainberg MA, Israel E, Schwartz Luft E. Differential expression of relevant Rous sarcoma tumor antigens in cultured cells Collect.Ann.Inst.Pasteur. 128: 101-104.  1
1976 Wainberg MA, Deutsch V, Weiss DW. Stimulation of anti-tumour immunity in guinea-pigs by methanol extraction residue of BCG British Journal of Cancer. 34: 500-508. PMID 187207 DOI: 10.1038/bjc.1976.202  1
1976 Wainberg MA, Minden P, Weiss DW. Vertical transmission of tumour resistance in guinea pigs Nature. 259: 213-215. PMID 175279 DOI: 10.1038/259213a0  1
1976 Wainberg MA, Phillips ER. Immunity against avian sarcomas: a review Israel Journal of Medical Sciences. 12: 388-406. PMID 59714  1
1973 Wainberg MA, Howe C. Factors affecting cell fusion induced by Sendai virus Journal of Virology. 12: 937-939. PMID 4359961  1
1973 Wainberg MA, Howe C, Godman GC. Enhancement of Sendai virus-mediated cell fusion by cupric ions Journal of Cell Biology. 57: 388-396. PMID 4348787  1
1973 Wainberg MA, Howe C. Infection-mediated resistance to cell fusion by inactive Sendai virus Proceedings of the Society For Experimental Biology and Medicine. 142: 981-987. PMID 4348100  1
1972 Wainberg MA, Howe C. Antibody-mediated fusion of FL amnion cells infected with parainfluenza virus type 2 Immunological Investigations. 1: 481-489. DOI: 10.3109/08820137209022958  1
1971 Wainberg MA, Erlanger BF. Investigation of the active center of trypsin using photochromic substrates Biochemistry. 10: 3816-3819. PMID 5160410  1
1971 Wainberg MA, Hjorth RN, Howe C. Effect of -propiolactone on Sendai virus Applied Microbiology. 22: 618-621. PMID 4331771  1
Show low-probability matches.